📰 Full Story
Multiple institutional investors adjusted holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) in filings published Feb. 3-5, 2026, reflecting active portfolio rebalancing after the company’s late-January earnings release and a $5 billion buyback authorization.
Reported moves include Bessemer Group marginally increasing its position to 540,350 shares (~$262.1m), Envestnet Asset Management reducing its stake by 9.2% to 568,471 shares (~$275.7m), and Zurcher Kantonalbank boosting its holding by 54.6% after purchasing 128,443 shares to reach 363,570 shares (~$210.7m). Smaller changes cited: TD Waterhouse Canada sold 1,765 shares, Hantz Financial cut its stake by 63.3% to 23,782 shares, Goldman Sachs’ equal-weight US large-cap ETF sold 794 shares, and Tred Avon Family Wealth added 738 shares.
Filings reiterate high institutional ownership (about 89.2%) and disclose significant insider selling in recent months (totaling roughly 124,517 shares, ~ $72.4m). Thermo Fisher reported Q4 2025 EPS of $6.57 and revenue of ~$12.2bn; shares have traded in a wide range, reflecting investor reassessment amid the buyback program.























💬 Commentary